ADMA Biologics (NASDAQ:ADMA) just reported results for the first quarter of 2024.
- ADMA Biologics reported earnings per share of 8 cents. This was above the analyst estimate for EPS of 5 cents.
- The company reported revenue of $81.88 million.
- This was 5.96% better than the analyst estimate for revenue of $77.27 million.